Indication:Untreated metastatic colorectal cancer
Other licensed indications
Pembrolizumab is recommended as an option for untreated metastatic colorectal cancer with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency in adults only if:
* pembrolizumab is stopped after 2 years and no documented disease progression
* the company provides pembrolizumab according to the commercial arrangement
NICE TA683 recommend pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer in adults whose tumours have no EGFR or ALK +ve mutations, only if it is stopped at 2 years of uninterrupted treatment, or earlier.
NICE TA661 Recommends pembrolizumab for untreated metastatitic/unresectable recurrent head and neck squamous cell carcinoma in adults with PD-L1+ve tumours.
NICE TA650 does not recommend pembrolizumab with axitinib for untreated advanced renal cell carcinoma in adults. Drug Safety Update
Reports of organ transplant rejection
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy